Amalgamated Financial’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Amalgamated Financial’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$16K	Buy	+3,462	New	+$15.6K	﹤0.01%	2805

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Amalgamated Financial's PSTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2022: 3,462 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #2805 among its holdings.

64 funds tracked by Wall St. Rank hold PSTX as of Q1 2022.

Amalgamated Financial held 3,462 shares of Poseida Therapeutics, Inc. Common Stock worth $16K as of Q1 2022.
Poseida Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Poseida Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2805 holding.
64 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.